Employees: 2,574
Size medmix (MEDX.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $494M, the 136th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 10.10 on 18 Nov 2026.
Performance Over six months the shares gained 11.2%, against -19.0% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue fell 6.6% over the last twelve months (peer median +7.0%); the operating margin is 6.3% (peer median 2.5%).
Valuation It trades at 19.4× forward earnings against a peer median of 22.4× (4th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.6 points below its cost of capital (5.0% WACC).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 437M | CHF 448M | CHF 484M | CHF 487M | CHF 477M |
| Revenue growth | — | -7% | -1% | +2% | — |
| Gross profit | CHF 160M | CHF 162M | CHF 160M | CHF 158M | CHF 175M |
| EBITDA | CHF 78.4M | CHF 79.7M | CHF 74.3M | CHF 68.4M | CHF 95.8M |
| Net income | CHF 100,000 | CHF 6.40M | -CHF 7.40M | CHF 300,000 | CHF 11.6M |
| Free cash flow | CHF 31.7M | CHF 33.3M | CHF 48.1M | CHF 9.70M | CHF 11.2M |
| Capital expenditure | CHF 32.0M | CHF 41.1M | CHF 48.5M | CHF 52.9M | CHF 38.6M |
| Total debt | n/a | CHF 330M | CHF 323M | CHF 350M | CHF 474M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MEDX.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | -5.9% | 4th highest of 21 |
| 6-month return | +11.2% | -19.0% | 5th highest of 21 |
| Distance from 52-week high | -18.3% | -40.9% | 4th highest of 21 |
| Revenue growth (TTM) | -6.6% | +7.0% | 5th lowest of 21 |
| Operating margin | 6.3% | 2.5% | 9th highest of 21 |
| Forward P/E | 19.4× | 22.4× | 4th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 4.5% | 6.6% | 5th least demanding of 11 |
| Growth delivered (Del g) | +5.0% | -0.1% | 5th highest of 11 |
| Hurdle (Req g minus delivered) | -0.5 pp | +6.8 pp | 5th least demanding of 11 |
| ROIC minus cost of capital | -1.6 pp | -1.6 pp | 9th lowest of 18 |
| EV / EBITDA | 8.1× | 12.5× | cheapest of 4 |
| Net debt / EBITDA | 2.6× | -1.7× | most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 6% | 19.4× | 4.5% | +5.0% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 3% | 25.8× | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 19.7× | 20.1% | +4.2% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -60% | n/a | n/a | n/a |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -51% | n/a | n/a | n/a |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 13% | 6.9× | -6.5% | -4.3% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 31% | 22.4× | 4.3% | +24.4% |
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | -8% | n/a | 30.8% | -18.6% |
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -4,880% | n/a | n/a | n/a |
| Shofu 7979.T | Japan | $510M | +32% | +9% | 14% | 13.2× | n/a | n/a |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -8% | n/a | 55.3% | -4.7% |
| Guangdong Hybribio Biotech 300639.SZ | China | $511M | -18% | -7% | 4% | 57.3× | 0.4% | -13.2% |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 23% | 32.6× | 7.1% | +10.0% |
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -6% | n/a | n/a | n/a |
| WELL LEAD MEDICAL 603309.SS | China | $473M | -22% | +1% | 15% | 11.9× | -5.9% | +7.7% |
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 67% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 2% | n/a | 6.0% | -7.7% |
| Eiken Chemical 4549.T | Japan | $466M | -20% | +4% | 6% | 24.5× | n/a | n/a |
| MiMedx MDXG | United States | $464M | -16% | -23% | -8% | n/a | 10.9% | +11.0% |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | n/a | n/a | n/a |